Cortexyme Inc.

93.65+1.50+1.63%Vol 203.64K1Y Perf 92.58%
Sep 24th, 2021 16:00 DELAYED
BID93.31 ASK93.65
Open90.28 Previous Close92.15
Pre-Market- After-Market-
 - -  - -%
Target Price
107.00 
Analyst Rating
Moderate Buy 1.67
Potential %
14.26 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-84 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-59 
Growth Ranking
★★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-47 
Income Ranking
 —    -
Price Range Ratio 52W %
70.28 
Earnings Rating
Strong Buy
Market Cap2.78B 
Earnings Date
11th Nov 2021
Alpha0.08 Standard Deviation0.34
Beta0.84 

Today's Price Range

90.2894.31

52W Range

26.66121.98

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
6.68%
1 Month
0.75%
3 Months
68.04%
6 Months
184.91%
1 Year
92.58%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CRTX93.651.50001.63
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.70-0.74-5.71
Q01 2021-0.63-0.78-23.81
Q03 2020-0.60-0.73-21.67
Q02 2020-0.63-0.604.76
Q01 2020-0.43-0.61-41.86
Q04 2019-0.39-0.46-17.95
Q03 2019--0.37-
----
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.709.09Positive
12/2021 QR-0.67-4.69Negative
12/2021 FY-2.95-2.08Negative
12/2022 FY-2.68-18.06Negative
Next Report Date11th Nov 2021
Estimated EPS Next Report-0.70
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume203.64K
Shares Outstanding29.69M
Shares Float17.10M
Trades Count4.17K
Dollar Volume11.98M
Avg. Volume266.52K
Avg. Weekly Volume231.78K
Avg. Monthly Volume243.22K
Avg. Quarterly Volume275.88K

Cortexyme Inc. (NASDAQ: CRTX) stock closed at 93.65 per share at the end of the most recent trading day (a 1.63% change compared to the prior day closing price) with a volume of 203.74K shares and market capitalization of 2.78B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 23 people. Cortexyme Inc. CEO is Casey C. Lynch.

The one-year performance of Cortexyme Inc. stock is 92.58%, while year-to-date (YTD) performance is 237.11%. CRTX stock has a five-year performance of %. Its 52-week range is between 26.66 and 121.98, which gives CRTX stock a 52-week price range ratio of 70.28%

Cortexyme Inc. currently has a PE ratio of -29.90, a price-to-book (PB) ratio of 18.34, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.67%, a ROC of -50.52% and a ROE of -50.01%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cortexyme Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.70 for the next earnings report. Cortexyme Inc.’s next earnings report date is 11th Nov 2021.

The consensus rating of Wall Street analysts for Cortexyme Inc. is Moderate Buy (1.67), with a target price of $107, which is +14.26% compared to the current price. The earnings rating for Cortexyme Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cortexyme Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cortexyme Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.08, ATR14 : 6.67, CCI20 : 12.04, Chaikin Money Flow : -0.14, MACD : 0.93, Money Flow Index : 46.15, ROC : 6.41, RSI : 55.94, STOCH (14,3) : 61.92, STOCH RSI : 1.00, UO : 51.54, Williams %R : -38.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cortexyme Inc. in the last 12-months were: Casey C. Lynch (Sold 120 000 shares of value $4 414 571 ), Christopher P. Lowe (Option Excercise at a value of $227 460), Christopher P. Lowe (Sold 42 000 shares of value $3 179 852 ), David A. Lamond (Buy at a value of $3 455 557), Leslie Holsinger (Option Excercise at a value of $11 745), Leslie Holsinger (Sold 40 000 shares of value $1 232 528 ), Margaret McLoughlin (Option Excercise at a value of $102 000), Margaret McLoughlin (Sold 6 550 shares of value $602 976 ), Michael Detke (Option Excercise at a value of $89 200), Michael Detke (Sold 68 261 shares of value $4 148 172 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Moderate Buy
1.67

Cortexyme Inc.

Cortexyme Inc is a clinical-stage biopharmaceutical company developing a disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases. Its approach is based on the seminal discovery of the presence of Porphyromonas gingivalis or P. gingivalis, and its secreted toxic virulence factor proteases called gingipains. The company operates in only one reportable segment that is developing and commercializing therapeutics.

CEO: Casey C. Lynch

Telephone: +1 415 910-5717

Address: 269 East Grand Avenue, South San Francisco 94080, CA, US

Number of employees: 23

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

33%67%

Bearish Bullish

52%48%

Bearish Bullish

57%43%

News

Stocktwits